CVRx, Inc. (CVRX) Company Overview

What does CVRx do?

CVRx, Inc. is a commercial-stage cardiovascular-device company listed on the Nasdaq Global Select Market under CVRX. It develops and commercializes Barostim, an implantable neuromodulation system for selected patients with heart failure with reduced ejection fraction, or HFrEF. Electrical pulses delivered to carotid baroreceptors help rebalance autonomic signaling. The therapy complements, rather than replaces, guideline-directed medical treatment.

The company’s stated mission centers on autonomic device therapies, while its vision is for Barostim to become a heart-failure standard of care. That goal drives spending on evidence, reimbursement, physician education, and direct sales.

Which patients and customers matter?

The approved U.S. population consists of symptomatic HFrEF patients who remain inadequately controlled despite medical therapy. Hospitals buy the system, but adoption requires coordination among heart-failure specialists, electrophysiologists, cardiologists, surgeons, and implant teams. Because CVRx estimates 67% of the target population is Medicare-eligible, reimbursement is a core commercial capability.

How does CVRx make money?

CVRx records product revenue when hospitals buy Barostim systems or replacement pulse generators. A full system includes a pulse generator and stimulation lead; battery replacement generally requires only a new generator after five to six years. Gross margin depends on selling price, channel and geographic mix, replacement mix, component cost, and manufacturing absorption.

Which geography drives revenue?

The U.S. drives the economics. FY2025 U.S. revenue was $51.9 million, or 91.6% of total revenue; Europe contributed $4.8 million, or 8.4%. The U.S. share rose to about 92.4% in Q1 2026, making reimbursement, territory productivity, hospital onboarding, and referrals more important than European currency effects.

What creates operating leverage?

Barostim carries strong product-level economics, but profitability requires revenue to outgrow commercial infrastructure. FY2025 gross profit was $48.3 million, compared with $88.5 million of SG&A and $11.1 million of R&D. The decisive question is whether each territory and center can generate enough volume to absorb fixed and semi-fixed costs.

Which turning points shaped CVRx’s strategy?

CVRx’s development is a sequence of regulatory and commercial de-risking events. It shifted from resistant hypertension toward HFrEF, obtained U.S. approval, and built reimbursement and sales capacity around one therapy. The 2025 Form 10-K connects those milestones to BENEFIT-HF.

1. 2011
   Barostim received a CE Mark for resistant hypertension, validating the platform’s regulatory pathway in Europe.
2. 2012
   European commercialization began, giving CVRx early implant and physician-support experience.
3. 2015
   The FDA granted Breakthrough Device designation for HFrEF, reinforcing the unmet-need rationale.
4. 2019
   Barostim received FDA premarket approval for heart failure, converting the company from development-stage to U.S. commercial-stage.
5. 2020
   U.S. commercialization began; direct selling, center activation, and reimbursement support became the main operating priorities.
6. 2023
   Expanded FDA labeling incorporated longer-term BeAT-HF results and clarified the approved use.
7. 2025
   CVRx received EU MDR approval and an FDA investigational device exemption for BENEFIT-HF; CMS also finalized new Category I CPT pricing.
8. 2026
   Category I CPT codes took effect January 1, and the first BENEFIT-HF site and patient moved the indication-expansion thesis into execution.

What does CVRx’s latest quarter show?

The quarter ended March 31, 2026 showed faster growth and better unit economics, but continuing losses. The Q1 2026 earnings release reported revenue of $14.8 million, up 20%. U.S. revenue rose 22% to $13.7 million on 429 units, while Europe declined 2% to $1.1 million on 56 units.

Why did gross margin improve?

An 87% gross margin indicates substantial contribution profit on incremental sales, yet $12.9 million of gross profit covered only about half of $25.0 million in Q1 operating expenses. FY2026 guidance remained $63-$67 million of revenue and $103-$107 million of operating expenses, with gross-margin guidance raised to 85%-87%. The company therefore still needs materially greater scale.

Barostim’s evidence, reimbursement, and competitive position

Barostim occupies a differentiated niche: symptomatic HFrEF patients with a narrow QRS complex who are generally not candidates for cardiac resynchronization therapy. CVRx estimates narrow-QRS patients represent about 59% of NYHA Class II or III patients with left-ventricular ejection fraction of 35% or less, creating a defined population not well served by conventional resynchronization.

How strong is the clinical evidence?

Across BAT-in-HF, HOPE4HF, and BeAT-HF, CVRx reports 624 patients in six countries and more than 65 peer-reviewed publications, about 25 in heart failure. Six-minute walk distance improved 56 meters versus controls at six months and 44 meters at one year, compared with a 25-meter threshold considered clinically meaningful. Implantation takes about one hour and patients are generally discharged within 24 hours. The official Barostim site summarizes patient outcomes and safety information.

Why is reimbursement part of the product?

For a costly implant, approval alone does not create demand; hospitals and physicians need workable payment and coding. In 2026, outpatient APC payment remained about $45,000 and inpatient MS-DRG 276 averaged about $44,000, versus a prior $17,000-$23,000 range. Category I CPT codes became effective January 1, 2026, which management expects to reduce automatic denials under the former Category III framework.

What gives CVRx a competitive advantage?

CVRx’s advantage is specialized rather than broad: first-in-category FDA approval, a differentiated mechanism, accumulated evidence, physician training, and reimbursement infrastructure. These assets reinforce one another because evidence supports coverage, coverage supports hospital adoption, and adoption builds experienced centers and real-world credibility.

Where does the moat remain incomplete?

Concentration also limits resilience. Almost all revenue depends on Barostim, while larger cardiovascular-device companies possess broader portfolios, deeper hospital relationships, and greater R&D budgets. CVRx must preserve clinical differentiation and service quality while making its commercial organization more productive.

How financially strong is CVRx?

CVRx has liquidity, a high gross margin, and improving growth, but it is not self-funding. At March 31, 2026, cash was $72.3 million, long-term debt carried at $58.5 million, and debt principal was $60.0 million. Q1 operating cash use was $12.2 million and capital spending was $0.1 million. Runway depends on revenue scaling and BENEFIT-HF spending.

How does cash convert through the model?

The Innovatus facility was amended in January 2026 for up to $100 million of aggregate principal, subject to milestones, with maturity extended to 2031; CVRx drew another $10 million. A Jefferies at-the-market program permits up to $50 million of equity sales. These tools add flexibility but can raise interest expense or dilution. The Q1 2026 Form 10-Q details liquidity and debt terms.

Who owns CVRx stock, and how is it governed?

CVRx has one common-stock class rather than founder-controlled dual-class voting. The 2026 proxy statement used 26.43 million shares outstanding on April 6, 2026. Johnson & Johnson owned 15.2%, New Enterprise Associates 7.7%, and Vensana Capital I 6.5%. Directors and executives as a group owned 16.6%, but that figure overlaps affiliated holdings.

What governance issues deserve attention?

Seven of eight directors in the 2026 slate were identified as independent; CEO Kevin Hykes was the sole non-independent director. Finance leadership became a watch item when CFO Jared Oasheim announced a planned departure. The June 2026 Form 8-K describes a successor search and transition support through February 2027. An orderly handoff matters for a cash-burning company using debt and equity facilities.

What opportunities and risks could change the story?

Where could growth come from?

BENEFIT-HF is the largest opportunity. It studies mortality and heart-failure decompensation in patients with ejection fractions up to 50% and NT-proBNP up to 5,000 pg/mL. Management estimates a potential U.S. prevalence opportunity of $30.5 billion and 983,000 patients, versus $10.5 billion and 339,000 under the current indication. These are company models, not guaranteed demand, but they show the trial’s strategic importance.

Which risks are most material?

The annual report states that CVRx expects significant losses for several years, depends on third-party manufacturers and limited suppliers, and may need more financing. Those risks directly reflect the simultaneous funding of a national commercial build and a long-duration indication-expansion trial.

Which KPIs and valuation drivers matter most?

Revenue growth alone does not explain CVRx. Researchers should separate access, utilization, unit economics, and financing. A useful operating identity is U.S. revenue equals active centers multiplied by implants per center multiplied by net revenue per unit. Territory growth creates access; profitability requires center and representative productivity to absorb SG&A.

What should the next earnings reports answer?

How should a DCF treat CVRx?

A disciplined DCF should separate the approved business from BENEFIT-HF optionality. The base case can use current centers, the existing indication, and near-term guidance. A probability-weighted scenario can reflect broader labeling, launch timing, trial spending, and failure risk. Negative free cash flow makes discount-rate, financing, and dilution assumptions unusually important.

What is the key takeaway from CVRx analysis?

CVRx has moved a differentiated implantable therapy from approval into measurable adoption. Q1 2026 revenue grew 20%, U.S. revenue grew 22%, active centers reached 257, and gross margin reached 87%. Those figures show expanding commercial activity and attractive product economics.

Scale remains the constraint. CVRx is a one-product company with a $12.2 million Q1 operating loss, $12.2 million of operating cash use, and $60 million of debt principal. More centers help, but implants per established center and revenue per territory must rise faster than the cost base.

The company’s investor-relations page provides the latest reporting package, filings, and scheduled earnings updates.